9BF9 image
Deposition Date 2024-04-17
Release Date 2024-12-25
Last Version Date 2024-12-25
Entry Detail
PDB ID:
9BF9
Keywords:
Title:
Human LAG-3-HLA-DR1 complex
Biological Source:
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.40 Å
R-Value Free:
0.25
R-Value Work:
0.20
R-Value Observed:
0.21
Space Group:
P 21 21 2
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:HLA class II histocompatibility antigen, DR alpha chain
Gene (Uniprot):HLA-DRA
Chain IDs:A
Chain Length:189
Number of Molecules:1
Biological Source:Homo sapiens
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:HLA class II histocompatibility antigen DR beta chain
Gene (Uniprot):HLA-DRB1
Chain IDs:B
Chain Length:211
Number of Molecules:1
Biological Source:Homo sapiens
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Lymphocyte activation gene 3 protein
Gene (Uniprot):LAG3
Chain IDs:D
Chain Length:418
Number of Molecules:1
Biological Source:Homo sapiens
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Membrane protein
Gene (Uniprot):M
Chain IDs:C (auth: G)
Chain Length:13
Number of Molecules:1
Biological Source:Severe acute respiratory syndrome coronavirus 2
Primary Citation
Crystal structure of the human LAG-3-HLA-DR1-peptide complex.
Sci Immunol 9 eads5122 eads5122 (2024)
PMID: 39671469 DOI: 10.1126/sciimmunol.ads5122

Abstact

T cell activity is governed by T cell receptor (TCR) signaling and constrained by immune checkpoint molecules, including programmed cell death protein 1 (PD-1), cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and lymphocyte activation gene 3 (LAG-3). The basis for how LAG-3 binds to human leukocyte antigen class II molecules (HLA-II) remains unknown. Here, we present the 3.4-angstrom crystal structure of a LAG-3-peptide-HLA-II complex and probe the energetics of the complex interface. Coincident with the HLA-II binding site of the ancestrally related, monomeric CD4 receptor, the LAG-3 homodimer laterally engages two HLA-II molecules via distal D1 domain surfaces, imposing a 38° angular offset. The LAG-3-HLA-II interface is discontinuous and lacks involvement of the D1 extra loop, a binding site for anti-LAG-3 therapeutic monoclonal antibodies. Upon HLA-II binding, intrinsically mobile loops of the LAG-3 molecule become ordered, with contact residues highly conserved across HLA-DR, DQ, and DP allomorphs. Our data provide a structural foundation for development of immunomodulatory approaches targeting LAG-3.

Legend

Protein

Chemical

Disease

Primary Citation of related structures